...
首页> 外文期刊>MIMS Doctor. >TWILIGHT: Ticagrelor monotherapy lowers bleeding incidence in high-risk patients after PCI
【24h】

TWILIGHT: Ticagrelor monotherapy lowers bleeding incidence in high-risk patients after PCI

机译:《暮光之城》:Ticagrelor单一疗法降低了出血发病率在高风险患者PCI

获取原文
获取原文并翻译 | 示例
           

摘要

In patients who underwent percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) with aspirin and the P2Y_12 receptor antagonist, ticagrelor, lowers the risk of ischaemic events. However, the risk of bleeding may be substantially increased. At the Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium 2019 held in California, US, Dr Roxana Mehran of the Mount Sinai Hospital in New York, US, presented results of the TWILIGHT (Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention) study, which demonstrated the benefits of ticagrelor monotherapy vs DAPT in reducing the risk of bleeding in patients who underwent PCI.
机译:在患者接受经皮冠状动脉介入治疗(PCI),双重抗血小板治疗(榫眼)与阿司匹林和P2Y_12受体拮抗剂,ticagrelor降低的风险缺血性事件。可能会大幅增加。心血管治疗肝(TCT)科学研讨会于2019年在加州举行,我们,罗克珊娜博士迈赫兰的西奈山医院纽约,美国,《暮光之城》的结果(Ticagrelor阿司匹林或高风险患者在冠状动脉介入)研究中,这证明ticagrelor的好处呢单一疗法和榫眼减少的风险出血的患者接受PCI。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号